EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare

The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.

The positive impact of these digital tools has been that they help patients …

/by

Inspiring a daughter to make her own path

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Teaching a daughter the power of purpose

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Challenging a young scientist to focus on patients

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Novartis announces change to the Executive Committee

  • Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021

  • Thomas Kendris appointed Chief Legal Officer ad interim

Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.

Thomas N. Kendris, currently Global Head Litigation and US Country President …

/by

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

  • Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.
  • Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from manufacturing site in Kundl, Austria expected to start in summer 2021.
  • One of several agreements Novartis is reviewing on a global basis to help …
/by

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

  • Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flow
  • Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election
  • Shareholders approve all other proposals of the Board of Directors, including the 2020 Compensation Report in an advisory vote, as well as the future Board and Executive …
/by

Take a visual tour of medicines that target RNA

Cells have a built-in search and delete function. The existence of such a system came as a surprise 30 years ago, when researchers experimenting with petunias discovered it accidentally.

Today, however, scientists are wielding that capability as powerful medicine.

Medicines that leverage this search and delete system are designed to block the production of disease-related proteins by targeting RNA, the instructions normally used by cells to build proteins. This new type of therapeutic has the potential to interrupt almost any disease process in the body. Novartis is developing …

/by

On a mission to transform planetary health

Illustration of planet earth

“Planetary health is directly related to human health and if we don’t change, the human species will disappear.” This was the stark warning delivered by Patrice Matchaba, Head, US Corporate Responsibility and President, Novartis US Foundation, at the inaugural One Young World (OYW)- …

/by

Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing

  • Adds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies
  • Novartis will co-develop tislelizumab with BeiGene and expand access to patients in North America, Europe and Japan
  • Specifically designed to minimize binding to FcγR on macrophages, tislelizumab will be key asset in Novartis immuno-oncology combination strategy

Basel, February 26, 2021 …

/by